This Collection is editorially independent, produced with financial support from a third party. About this content.
Cracking the Code: The Dawn of Nucleic Acid Medicines
The conference will discuss the development of nucleic acid medicines — both the recent clinical successes, and current and upcoming challenges. By bringing together academics in basic and translational research and their peers in thriving biotechnology companies and promising start-ups, the conference aims to foster dialog and to spearhead collaborations. The first day (October 17, 2023) will bring awareness of R&D driven by biotechnology companies developing nucleic acid medicines, and discuss career paths for students and early career researchers to become the next-generation of leaders in biotechnology. The following two days will discuss what should be learnt from late-stage and approved nucleic acid gene therapies and vaccines, and highlight promising preclinical therapeutic modalities — in particular, genome and epigenome editing, and the design of new RNA therapeutics — and machine learning and bioinformatic tools accelerating the development of emerging nucleic acid therapies and vaccines.